

2023, Publikationserhebung, Allgemeine Pathologie Heidelberg

Rot: Erst/Letztautorenschaft

*geteilte Erst- oder Letztautorenschaft

1. Ahadova A, **Stenzinger A**, Seppälä T, Hüneburg R, Kloor M, Bläker H; **Lynpath Investigators**. A "Two-in-One Hit" Model of Shortcut Carcinogenesis in MLH1 Lynch Syndrome Carriers. *Gastroenterology*. 2023 Jul;165(1):267-270.e4. (IF 29,4)
2. Ahadova A, **Stenzinger A**, Seppälä T, Hüneburg R, Kloor M, Bläker H. Das Two-in-one-hit-Modell der beschleunigten Genese von kolorektalen Karzinomen beim MLH1-assoziierten Lynch-Syndrom [The two-in-one hit model of the short-cut carcinogenesis of colorectal carcinomas in MLH1-associated Lynch syndrome]. *Pathologie (Heidelb)*. 2023 Dec;44(Suppl 3):188-192. (IF 1,0)
3. Albrecht M, Sticht C, Wagner T, Hettler SA, De La Torre C, Qiu J, Gretz N, **Albrecht T**, Yard B, Sleeman JP, Garvalov BK. The crosstalk between glomerular endothelial cells and podocytes controls their responses to metabolic stimuli in diabetic nephropathy. *Sci Rep*. 2023 Oct 20;13(1):17985. (IF 4,6)
4. **Albrecht T, Rossberg A, Albrecht JD, Nicolay JP, Straub BK, Gerber TS, Albrecht M, Brinkmann F, Charbel A, Schwab C, Schreck J, Brobeil A, Flechtenmacher C, von Winterfeld M, Köhler BC, Springfield C, Mehrabi A, Singer S, Vogel MN, Neumann O, Stenzinger A, Schirmacher P, Weis CA, Roessler S, Kather JN, Goepfert B**. Deep Learning-Enabled Diagnosis of Liver Adenocarcinoma. *Gastroenterology*. 2023 Nov;165(5):1262-1275. (IF 29,4)
5. Alonso de la Vega A, Temiz NA, Tasakis R, Somogyi K, Salgueiro L, Zimmer E, Ramos M, Diaz-Jimenez A, Chocarro S, Fernández-Vaquero M, Stefanovska B, Reuveni E, Ben-David U, **Stenzinger A, Poth T**, Heikenwälder M, Papavasiliou N, Harris RS, Sotillo R. Acute expression of human APOBEC3B in mice results in RNA editing and lethality. *Genome Biol*. 2023 Nov 24;24(1):267. (IF 12,3)
6. Altea-Manzano P, Doglioni G*, Liu Y*, Cuadros AM, Nolan E, Fernández-García J, Wu Q, Planque M, Laue KJ, Cidre-Aranaz F, Liu XZ, Marin-Bejar O, Van Elsen J, Vermeire I, Broekaert D, Demeyer S, Spotbeen X, Idkowiak J, Montagne A, Demicco M, Alkan HF, Rabas N, Riera-Domingo C, Richard F, Geukens T, De Schepper M, Leduc S, Hatse S, Lambrechts Y, Kay EJ, Lilla S, Alekseenko A, Geldhof V, Boeckx B, de la Calle Arregui C, Floris G, Swinnen JV, Marine JC, Lambrechts D, Pelechano V, Mazzone M, Zanivan S, Cools J, Wildiers H, Baud V, **Grünewald TGP**, Ben-David U, Desmedt C, Malanchi I, Fendt SM. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling. *Nat Cancer*. 2023 Mar;4(3):344-364. (IF 22,7)
7. Alwers E, Kather JN, Kloor M, **Brobeil A**, Tagscherer KE, Roth W, Echle A, Amitay EL, Chang-Claude J, Brenner H, Hoffmeister M. Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study. *J Pathol Clin Res*. 2023 Mar;9(2):129-136. (IF 4,1)
8. **Arnscheidt J, Winter H, Grott M, Kriegsmann K, Heußel CP, Kriegsmann M**. Multiple Lungenrundherde bei einem 61-jährigen Patienten [Multiple pulmonary nodules in a 61-year-old patient]. *Radiologie (Heidelb)*. 2023 Jul;63(7):539-542. German. (IF 0,7)
9. **Baker EAG*, Schapiro D***, Dumitrascu B, Vickovic S, Regev A. In silico tissue generation and power analysis for spatial omics. *Nat Methods*. 2023 Mar;20(3):424-431. (IF 48,0)
10. Baltzer AW, Casadonte R, Korff A, Baltzer LM, Kriegsmann K, **Kriegsmann M**, Kriegsmann J. Biological injection therapy with leukocyte-poor platelet-rich plasma induces cellular alterations, enhancement of lubricin, and inflammatory downregulation *in vivo* in human knees: A controlled, prospective human clinical trial based on mass spectrometry imaging analysis. *Front Surg*. 2023 Apr 21;10:1169112. (IF 1,8)

11. Baretton GB, Lordick F; Interdisciplinary Expert Group; Gaiser T, Hofheinz R, Horst D, Lorenzen S, Moehler M, Röcken C, **Schirmacher P**, Stahl M, Thuss-Patience P, Tiemann K. Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. *J Cancer Res Clin Oncol.* 2023 Nov;149(17):16231-16238. (IF 3,6)
12. Benning L, Morath C, Fink A, Rudek M, Speer C, Kälble F, Nussbag C, Beimler J, **Schwab C, Waldherr R**, Zeier M, Süsal C, Tran TH. Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients With Indication Biopsy-Results of a Prospective Single-Center Trial. *Transpl Int.* 2023 Nov 3;36:11899. (IF 3,1)
13. Berbís MA, McClintock DS, Bychkov A, Van der Laak J, Pantanowitz L, Lennerz JK, Cheng JY, Delahunt B, Egevad L, Eloy C, Farris AB 3rd, Fraggetta F, García Del Moral R, Hartman DJ, Herrmann MD, Hollemans E, Iczkowski KA, Karsan A, **Kriegsmann M**, Salama ME, Sinard JH, Tuthill JM, Williams B, Casado-Sánchez C, Sánchez-Turrión V, Luna A, Aneiros-Fernández J, Shen J. Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade. *EBioMedicine.* 2023 Feb;88:104427. (IF 11,1)
14. Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Kautz A, Krug D, Fougère C, Lang H, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion. *Z Gastroenterol.* 2023 Apr;61(4):e92-e156. (IF 1,3)
15. Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Kautz A, Krug D, Fougère C, Lang H, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome- Kurzversion. *Z Gastroenterol.* 2023 Apr;61(4):420-440. (IF 1,3)
16. Blasi M*, Kuon J*, Shah R, Bozorgmehr F, Eichhorn F, Liersch S, **Stenzinger A**, Heußel CP, Herth FJ, Thomas M, Christopoulos P. Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study. *Clin Lung Cancer.* 2023 Nov;24(7):e282-e290. (IF 3,6)
17. Calvisi DF, Boulter L, Vaquero J, Saborowski A, Fabris L, Rodrigues PM, Coulouarn C, Castro RE, Segatto O, Raggi C, van der Laan LJW, Carpino G, **Goeppert B, Roessler S**, Kendall TJ, Evert M, Gonzalez-Sanchez E, Valle JW, Vogel A, Bridgewater J, Borad MJ, Gores GJ, Roberts LR, Marin JJG, Andersen JB, Alvaro D, Forner A, Banales JM, Cardinale V, Macias RIR, Vicent S, Chen X, Braconi C, Verstegen MMA, Fouassier L; CCA Model Consortium. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. *Nat Rev Gastroenterol Hepatol.* 2023 Jul;20(7):462-480. (IF 65,1)
18. Casadonte R, Kriegsmann J, **Kriegsmann M**, Kriegsmann K, Torcasio R, Gallo Cantafio ME, Viglietto G, Amodio N. A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells. *Cancers (Basel).* 2023 Feb 3;15(3):974. (IF 5,2)
19. Casadonte R, **Kriegsmann M**, Kriegsmann K, Streit H, Meli RR, Müller CSL, Kriegsmann J. Imaging Mass Spectrometry for the Classification of Melanoma Based on *BRAF/NRAS* Mutational Status. *Int J Mol Sci.* 2023 Mar 7;24(6):5110. (IF 5,6)

20. Ceranski AK, Carreño-Gonzalez MJ, Ehlers AC, Colombo MV, Cidre-Aranaz F, **Grünewald TGP**. Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship. *Mol Cancer*. 2023 Mar 13;22(1):49. (IF 37,3)
21. Christopoulos P, Prawitz T, Hong JL, Lin HM, Hernandez L, Jin S, Tan M, Proskorovsky I, Lin J, Zhang P, Patel JD, Ou SI, Thomas M*, **Stenzinger A***. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations. *Lung Cancer*. 2023 May;179:107191. (IF 5,3)
22. Christopoulos P, Schlenk R, **Kazdal D**, Blasi M, Lennerz J, Shah R, **Budczies J**, Malek N, Fröhling S, Rosenquist R, **Schirmacher P**, Bozorgmehr F, Kuon J, Reck M, Thomas M, **Stenzinger A**. Real-world data for precision cancer medicine-A European perspective. *Genes Chromosomes Cancer*. 2023 Sep;62(9):557-563. (IF 3,7)
23. Conche C*, Finkelmeier F*, Pešić M, Nicolas AM, Böttger TW, Kennel KB, Denk D, Ceteci F, Mohs K, Engel E, Canli Ö, Dabiri Y, Peiffer KH, Zeuzem S, Salinas G, **Longerich T**, Yang H, Greten FR. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. *Gut*. 2023 Sep;72(9):1774-1782. (IF 24,5)
24. D'Artista L, Moschopoulou AA, Barozzi I, Craig AJ, Seehawer M, Herrmann L, Minnich M, Kang TW, Rist E, Henning M, Klotz S, Heinzmann F, Harbig J, Sipos B, **Longerich T**, Eilers M, Dauch D, Zuber J, Wang XW, Zender L. MYC determines lineage commitment in KRAS-driven primary liver cancer development. *J Hepatol*. 2023 Jul;79(1):141-149. (IF 25,7)
25. de Bortoli T, Benary M, Horak P, Lamping M, Stintzing S, Tinhofer I, Leyvraz S, Schäfer R, Klauschen F, Keller U, **Stenzinger A**, Fröhling S, Kurzrock R, Keilholz U, Rieke DT*, Jelas I*. Tumour mutational burden and survival with molecularly matched therapy. *Eur J Cancer*. 2023 Sep;190:112925. (IF 8,4)
26. Dermawan JK, Dashti N, Chiang S, Turashvili G, Dickson BC, Ellenson LH, **Kirchner M**, **Stenzinger A**, **Mechtersheimer G**, Agaimy A, Antonescu CR. Expanding the molecular spectrum of gene fusions in endometrial stromal sarcoma: Novel subunits of the chromatin remodeling complexes PRC2 and NuA4/TIP60 as alternative fusion partners. *Genes Chromosomes Cancer*. 2023 Mar;62(3):152-160. (IF 3,7)
27. Dietel M, **Schirmacher P**, Mogler C; Institut für Pathologie der TU München. Wilko Weichert : 22.09.1970–10.07.2023. *Pathologie (Heidelb)*. 2023 Dec;44(Suppl 3):277-278. (IF 1,0)
28. Dieterle MP, Husari A, Prozmann SN, **Wiethoff H**, **Stenzinger A**, Röhrich M, Pfeiffer U, Kießling WR, Engel H, Sourij H, Steinberg T, Tomakidi P, Kopf S, Szendroedi J. Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia. *Biomedicines*. 2023 Jun 16;11(6):1732. (IF 4,7)
29. Dieterle MP, Husari A, Prozmann SN, **Wiethoff H**, **Stenzinger A**, Röhrich M, Pfeiffer U, Kießling WR, Engel H, Sourij H, Steinberg T, Tomakidi P, Kopf S, Szendroedi J. An Uncommon Cause of Recurrent Presyncope, Dizziness, and Tachycardia: A Case Report of Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS). *Biomedicines*. 2023 Jun 17;11(6):1741. (IF 4,7)
30. Doolan BJ, Lavallee M, **Hausser I**, Pope FM, Seneviratne SL, Winship IM, Burrows NP. Dermatologic manifestations and diagnostic assessments of the Ehlers-Danlos syndromes: A clinical review. *J Am Acad Dermatol*. 2023 Sep;89(3):551-559. (IF 13,8)
31. Doolan BJ, Lavallee ME, **Hausser I**, Schubart JR, Michael Pope F, Seneviratne SL, Winship IM, Burrows NP. Extracutaneous features and complications of the Ehlers-Danlos syndromes: A systematic review. *Front Med (Lausanne)*. 2023 Jan 23;10:1053466. (IF 3,9)
32. Dragani TA*, Muley T*, Schneider MA, Kobinger S, Eichhorn M, Winter H, Hoffmann H, **Kriegsmann M**, Noci S, Incarbone M, Tosi D, Franzi S, Colombo F. Lung Adenocarcinoma Diagnosed at a Younger Age Is Associated with Advanced Stage, Female Sex, and Ever-Smoker Status, in Patients Treated with Lung Resection. *Cancers (Basel)*. 2023 Apr 21;15(8):2395. (IF 5,2)
33. Dragomir MP, Calina TG, Perez E, Schallenberg S, Chen M, **Albrecht T**, Koch I, Wolkenstein P, **Goeppert B**, **Roessler S**, Calin GA, Sers C, Horst D, Roßner F, Capper D. DNA methylation-based

- classifier differentiates intrahepatic pancreato-biliary tumours. *EBioMedicine*. 2023 Jul;93:104657. (IF 4,7)
34. Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabières C, **Ploeger C**, Lassen U, Le Tourneau C, Lehtiö J, Ott PA, von Deimling A, Fröhling S, Voest E, Klauschen F, Dienstmann R, Alshibany A, Siu LL, **Stenzinger A**. Precision cancer medicine: Concepts, current practice, and future developments. *J Intern Med*. 2023 Oct;294(4):455-481. (IF 11,1)
 35. Eichhorn F, Weigert A, Nandigama R, Klotz LV, Wilhelm J, **Kriegsmann M**, **Allgäuer M**, Muley T, Christopoulos P, Savai R, Eichhorn ME, Winter H. Prognostic Impact of the Immune-Cell Infiltrate in N1-Positive Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2023 Dec;24(8):706-716.e1. (IF 3,6)
 36. Emde-Rajaratnam M, **Beck S**, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A*, Hose D*. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. *Front Immunol*. 2023 Nov 15;14:1286700. (IF 7,3)
 37. Fasching PA*, Szeto C*, Denkert C, Benz S, Weber K, Spilman P, **Budczies J**, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, **Sinn HP**, Warm M, van Mackelenbergh M, Rabizadeh S, Schem C, Heinmöller E, Mueller V, Marmé F, Soon-Shiong P, Nekljudova V, Untch M*, Loibl S*. Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial. *Clin Cancer Res*. 2023 Jul 5;29(13):2456-2465. (IF 11,5)
 38. Friedhoff J, Schneider F, Jurcic C, **Endris V**, **Kirchner M**, Sun A, Bolnavu I, Pohl L, Teroerde M, Kippenberger M, **Schwab C**, Kaczorowski A, Zschäbitz S, Jäger D, Hohenfellner M, **Stenzinger A***, **Duensing A***, **Duensing S***. BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study. *Cancer Immunol Immunother*. 2023 Jun;72(6):1603-1618. (IF 5,8)
 39. Gahlawat AW, Witte T, **Sinn P**, Schott S. Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer. *Sci Rep*. 2023 Apr 4;13(1):5503. (IF 4,6)
 40. Giesen N, Chatterjee M, Scheid C, Poos AM, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kortüm KM, Müller-Tidow C, **Mechtersheimer G**, **Goeppert B**, **Stenzinger A**, Weinhold N, Goldschmidt H, Weisel K, Raab MS. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. *Blood*. 2023 Apr 6;141(14):1685-1690. (IF 20,3)
 41. **Goldschmid H**, **Kluck K**, **Ball M**, **Kirchner M**, **Allgäuer M**, Winter H, Herth F, Heußel CP, Pullamsetti SS, Savai R, **Yong TTK**, **Schirmacher P**, Peters S, Thomas M, Christopoulos P, **Budczies J**, **Stenzinger A**, **Kazdal D**. Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas. *Lung Cancer*. 2023 Jun;180:107212. (IF 5,3)
 42. Görtz M, Huber AK, Linz T, **Schwab C**, **Stenzinger A**, Goertz L, Bonekamp D, Schlemmer HP, Hohenfellner M. Detection Rate of Prostate Cancer in Repeat Biopsy after an Initial Negative Magnetic Resonance Imaging/Ultrasound-Guided Biopsy. *Diagnostics (Basel)*. 2023 May 17;13(10):1761. (IF 3,6)
 43. Griger J, Widholz SA, Jesinghaus M, de Andrade Krätzig N, Lange S, Engleitner T, Montero JJ, Zhigalova E, Öllinger R, Suresh V, Winkler W, Lier S, Baranov O, Trozzo R, Ben Khaled N, Chakraborty S, Yu J, Konukiewitz B, Steiger K, Pfarr N, Rajput A, Sailer D, Keller G, **Schirmacher P**, Röcken C, Fagerstedt KW, Mayerle J, Schmidt-Supprian M, Schneider G, Weichert W, Calado DP, Sommermann T, Klöppel G, Rajewsky K, Saur D, Rad R. An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets. *Cancer Cell*. 2023 Jul 10;41(7):1327-1344.e10. (IF 50,3)
 44. Grube I, **Antonopoulos W**, Kölmel JC, Rüller K, Fiz F, Piazza C, Peretti G, **Flechtenmacher C**, **Schirmacher P**, Sittel C. Hormone pathway comparison in non-idiopathic and idiopathic progressive subglottic stenosis. *Eur Arch Otorhinolaryngol*. 2023 Feb;280(2):775-780. (IF 2,6)

45. Grube M, Reijnen C, Lucas PJF, Kommos F, **Kommos FKF**, Brucker SY, Walter CB, Oberlechner E, Krämer B, Andress J, Neis F, Staebler A, Pijnenborg JMA, Kommos S. Improved preoperative risk stratification in endometrial carcinoma patients: external validation of the ENDORISK Bayesian network model in a large population-based case series. *J Cancer Res Clin Oncol*. 2023 Jul;149(7):3361-3369. (IF 3,6)
46. Guimarães LM, Baumhoer D, Andrei V, Friedel D, **Koelsche C**, Gomez RS, von Deimling A, Gomes CC. DNA methylation profile discriminates sporadic giant cell granulomas of the jaws and cherubism from their giant cell-rich histological mimics. *J Pathol Clin Res*. 2023 Nov;9(6):464-474. (IF 4,1)
47. **Gutjahr E, Fremd C, Arnscheidt J, Penzel R, Wacker J, Sinn P**. Non-Response of Epstein-Barr Virus-Associated Breast Cancer after Primary Chemotherapy: Report of Two Cases. *Pathogens*. 2023 Nov 24;12(12):1387. (IF 3,7)
48. Hank T*, Klaiber U*, Hinz U, Schütte D, Leonhardt CS, **Bergmann F**, Hackert T, Jäger D, Büchler MW, Strobel O. Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. *Ann Surg*. 2023 May 1;277(5):e1089-e1098. (IF 10,1)
49. Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Calìo A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, **Kazdal D**, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuurin E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, **Stenzinger A**, Ilić M. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. *ESMO Open*. 2023 Oct;8(5):101628. (IF 7,3)
50. Hohmann N*, Sprick MR*, Pohl M, Ahmed A, Burhenne J, Kirchner M, Le Cornet L, Kratzmann M, Hajda J, **Stenzinger A**, Steindorf K, Delorme S, Schlemmer HP, Riethdorf S, van Schaik R, Pantel K, Siveke J, Seufferlein T, Jäger D, Haefeli WE, Trumpp A*, Springfield C*. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy. *Clin Transl Sci*. 2023 Dec;16(12):2483-2493. (IF 3,9)
51. Hoppner J, van Genabith L, Hielscher T, Heger U, Sperling L, Colbatzky T, **Gutjahr E**, Lang M, Pausch T, Spektor AM, Glatting FM, Liermann J, Hackert T, Kratochwil C, Giesel FL, Haberkorn U, Röhrich M. Comparison of early and late ⁶⁸Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas. *Sci Rep*. 2023 Oct 19;13(1):17848. (IF 4,6)
52. **Huth T, Dreher EC, Lemke S, Fritzsche S, Sugiyanto RN, Castven D, Ibberson D, Sticht C, Eiteneuer E, Jauch A, Pusch S, Albrecht T, Goepfert B, Candia J, Wang XW, Ji J, Marquardt JU, Nahnsen S, Schirmacher P, Roessler S**. Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer. *Sci Adv*. 2023 Dec 22;9(51):eadh1442. (IF 13,6)
53. Illert AL, **Stenzinger A**, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, **Budczies J**, Werner M, Nikolaou K, Beer AJ, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, **Schirmacher P**, Malek

- NP. The German Network for Personalized Medicine to enhance patient care and translational research. *Nat Med*. 2023 Jun;29(6):1298-1301. (IF 82,9)
54. Jank P*, Leichsenring J*, Kolb S, Hoffmann I, Bischoff P, Kunze CA, Dragomir MP, Gleitsmann M, Jesinghaus M, Schmitt WD, Kulbe H, Sers C, **Stenzinger A**, Sehoul J, Braicu IE, Westhoff C, Horst D, Denkert C, Gröschel S*, Taube ET*. High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma. *J Ovarian Res*. 2023 Jul 31;16(1):150. (IF 4,0)
 55. John L*, Poos AM*, **Brobeil A**, Schinke C, Huhn S, Prokoph N, Lutz R, Wagner B, Zangari M, Tirier SM, Mallm JP, Schumacher S, Vonficht D, Solé-Boldo L, Quick S, Steiger S, Przybilla MJ, Bauer K, Baumann A, Hemmer S, Rehnitz C, Lücknerath C, Sachpekidis C, **Mechtersheimer G**, Haberkorn U, Dimitrakopoulou-Strauss A, Reichert P, Barlogie B, Müller-Tidow C, Goldschmidt H, Hillengass J, Rasche L, Haas SF, van Rhee F, Rippe K, Raab MS, Sauer S, Weinhold N. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. *Nat Commun*. 2023 Aug 17;14(1):5011. (IF 16,6)
 56. **Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, Budczies J, Kempny G, Kazmierczak M, Flechtenmacher C, Baretton G, Weichert W, Horst D, Klauschen F, Gassner UM, Brüggemann M, Vogeser M, Schirmacher P, Stenzinger A**. Structure and content of the EU-IVDR : Current status and implications for pathology. *Pathologie (Heidelb)*. 2023 Nov;44(Suppl 2):73-85. (IF 1,0)
 57. **Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, Budczies J, Flechtenmacher C, Gassner UM, Brüggemann M, Vogeser M, Schirmacher P, Stenzinger A**. Regulation (EU) 2017/746 (IVDR): practical implementation of annex I in pathology. *Pathologie (Heidelb)*. 2023 Nov;44(Suppl 2):86-95. (IF 1,0)
 58. **Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, Budczies J, Flechtenmacher C, Gassner UM, Brüggemann M, Vogeser M, Schirmacher P, Stenzinger A**. Die Verordnung (EU) 2017/746 (IVDR) in der Praxis: Umsetzung von Anhang I in der Pathologie [Regulation (EU) 2017/746 (IVDR): practical implementation of annex I in pathology]. *Pathologie (Heidelb)*. 2023 Nov;44(6):381-391. (IF 1,0)
 59. Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCs Group; Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, **Kommoss FKF**, Kruitwagen RFP, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van Wageningen L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommoss S, Menon U, **Sinn HP**, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. *Cancer*. 2023 Mar 1;129(5):697-713. (IF 6,2)
 60. **Kazdal D, Menzel M, Budczies J, Stenzinger A**. Molekulare Tumordiagnostik als Triebfeder der Präzisionsonkologie [Molecular tumor diagnostics as the driving force behind precision oncology]. *Dtsch Med Wochenschr*. 2023 Sep;148(18):1157-1165. (IF 0,6)

61. Khajeh E, Aminizadeh E, Moghadam AD, Ramouz A, Klotz R, Golriz M, Merle U, Springfield C, Chang DH, **Longerich T**, Büchler MW, Mehrabi A. Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis. *Cancer Med.* 2023 Oct;12(19):19548-19559. (IF 4,0)
62. Klümper N*, Ralser DJ*, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, **Schwab C**, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M*, Eckstein M*. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. *Clin Cancer Res.* 2023 Apr 14;29(8):1496-1505. (IF 11,5)
63. Köhrer S*, Dittrich T*, Schorb M, Weinhold N, Haberbosch I, Börmel M, Pajor G, Goldschmidt H, Müller-Tidow C, Raab MS, John L, Seckinger A, **Brobeil A**, Dreger P, Tornóczy T, Pajor L, Hegenbart U, Schönland SO, Schwab Y, Krämer A. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders. *Leukemia.* 2023 Dec;37(12):2468-2478. (IF 11,4)
64. **Kommos FKF**, Chong AS, Chong AL, Pfaff E, Jones DTW, Hiemcke-Jiwa LS, Kester LA, Flucke U, Gessler M, Schrimpf D, Sahm F, Clarke BA, Stewart CJR, Wang Y, Gilks CB, Kommos F, Huntsman DG, Schüller U, **Koelsche C**, McCluggage WG, von Deimling A*, Foulkes WD*. Genomic characterization of DICER1-associated neoplasms uncovers molecular classes. *Nat Commun.* 2023 Mar 25;14(1):1677. (IF 16,6)
65. **Kommos FKF**, Mar LM, Howitt BE, Hanley K, Turashvili G, Buslei R, Irving JA, Dickson BC, **Koelsche C**, Sinn HP, **Schirmacher P**, von Deimling A, Chiang S, McCluggage WG, Croce S, Stewart CJR, Lee CH. High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of p16 Staining is a Poor Prognostic Marker. *Mod Pathol.* 2023 Mar;36(3):100044. (IF 7,5)
66. **Kommos FKF**, Schmidt D, Kommos F, Tessier-Cloutier B. Small-cell carcinoma of the ovary hypercalcaemic type shows a wild-type immunohistochemical staining pattern of p53. *Histopathology.* 2023 Jul;83(1):154-156. (IF 6,4)
67. Kovacs B, Netzer N, Baumgartner M, Schrader A, Isensee F, Weißer C, Wolf I, Görtz M, Jaeger PF, Schütz V, Floca R, Gnirs R, **Stenzinger A**, Hohenfellner M, Schlemmer HP, Bonekamp D*, Maier-Hein KH*. Addressing image misalignments in multi-parametric prostate MRI for enhanced computer-aided diagnosis of prostate cancer. *Sci Rep.* 2023 Nov 13;13(1):19805. (IF 4,6)
68. **Kriegsmann M***, Kriegsmann K*, Steinbuss G*, **Zgorzelski C**, **Albrecht T**, Heinrich S, Farkas S, Roth W, Dang H, Hausen A, Gaida MM. Implementation of deep learning in liver pathology optimizes diagnosis of benign lesions and adenocarcinoma metastasis. *Clin Transl Med.* 2023 Jul;13(7):e1299. (IF 10,6)
69. Lang M, **Kazdal D**, Mohr I, Anamaterou C. Differences and similarities of *GTF2I* mutated thymomas in different Eurasian ethnic groups. *Transl Lung Cancer Res.* 2023 Sep 28;12(9):1842-1844. doi: 10.21037/tlcr-23-396. (IF 4,0)
70. Lang M, **Longerich T**, Anamaterou C. Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer. *Thyroid Res.* 2023 Mar 1;16(1):5. (IF 2,2)
71. Lang M, Spektor AM, Hielscher T, Hoppner J, Glatting FM, Bicu F, Hackert T, Heger U, Pausch T, **Gutjahr E**, Rathke H, Giesel FL, Kratochwil C, Tjaden C, Haberkorn U, Röhrich M. Static and Dynamic ⁶⁸Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas. *J Nucl Med.* 2023 Feb;64(2):244-251. (IF 9,3)
72. Lederer C, Mayer K, Somogyi V, Kriegsmann K, **Kriegsmann M**, Buschulte K, Polke M, Findeisen P, Herth F, Kreuter M. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases. *Respiration.* 2023;102(8):591-600. (IF 3,7)
73. Lee OW*, Rodrigues C*, Lin SH, Luo W, Jones K, Brown DW, Zhou W, Karlins E, Khan SM, Baulande S, Raynal V, Surdez D, Reynaud S, Rubio RA, Zaidi S, Grossetête S, Ballet S, Lapouble E,

- Laurence V, Pierron G, Gaspar N, Corradini N, Marec-Bérard P, Rothman N, Dagnall CL, Burdett L, Manning M, Wyatt K, Yeager M, Chari R, Leisenring WM, Kulozik AE, Kriebel J, Meitinger T, Strauch K, Kirchner T, Dirksen U, Mirabello L, Tucker MA, Tirode F, Armstrong GT, Bhatia S, Robison LL, Yasui Y, Romero-Pérez L, Hartmann W, Metzler M, Diver WR, Lori A, Freedman ND, Hoover RN, Morton LM, Chanock SJ, **Grünewald TGP**, Delattre O, Machiela MJ. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding. *Am J Hum Genet.* 2023 Mar 2;110(3):427-441. (IF 9,8)
74. **Lehmann U, Stenzinger A.** Der Biomarker IDH1/2 in der Tumorpathologie [The IDH1/2 biomarker in tumor pathology]. *Pathologie (Heidelb).* 2023 Sep;44(5):318-319. (IF 1,0)
75. **Lehmann U, Stenzinger A.** Der Biomarker PIK3CA in der Tumorpathologie [The biomarker PIK3CA in tumor pathology]. *Pathologie (Heidelb).* 2023 Jul;44(4):259-260. (IF 1,0)
76. Leonhardt CS, Hinz U, Kaiser J, Hank T, Tjaden C, **Bergmann F**, Hackert T, Büchler MW, Strobel O. Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcinoma. *Eur J Surg Oncol.* 2023 Jan;49(1):113-121. (IF 3,8)
77. Levai E*, Marinovic I*, Bartosova M*, Zhang C, Schaefer B, Jenei H, Du Z, Drozd D, Klaus G, Arbeiter K, Romero P, Schwenger V, **Schwab C**, Szabo AJ, Zarogiannis SG*, Schmitt CP*. Human peritoneal tight junction, transporter and channel expression in health and kidney failure, and associated solute transport. *Sci Rep.* 2023 Oct 13;13(1):17429. (IF 4,6)
78. Longuespée R, Kunz J, Fresnais M, Foerster KI, Burhenne J, Thomas M, **Kazdal D, Stenzinger A**, Christopoulos P, Haefeli WE. Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report. *Br J Clin Pharmacol.* 2024 Jan;90(1):344-349. (IF 3,4)
79. Loos M*, König AK*, von Winkler N, Mehrabi A, Berchtold C, Müller-Stich BP, Schneider M, Hoffmann K, Kulu Y, Feisst M, Hinz U, Lang M, **Goepfert B, Albrecht T**, Strobel O, Büchler MW, Hackert T. Completion Pancreatectomy After Pancreatoduodenectomy: Who Needs It? *Ann Surg.* 2023 Jul 1;278(1):e87-e93. (IF 10,1)
80. Maichl DS*, Kirner JA*, **Beck S***, Cheng WH, Krug M, Kuric M, Ade CP, Bischler T, Jakob F, Hose D, Seckinger A, Ebert R, Jundt F. Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival. *Blood Cancer J.* 2023 Sep 5;13(1):134. (IF 12,8)
81. Mehrabi A, Golriz M, Ramouz A, Khajeh E, Hammad A, Hackert T, Müller-Stich B, Strobel O, Ali-Hasan-Al-Saegh S, Ghamarnejad O, Al-Saedi M, Springfield C, Rupp C, Mayer P, Mieth M, **Goepfert B**, Hoffmann K, Büchler MW. Promising Outcomes of Modified ALPPS for Staged Hepatectomy in Cholangiocarcinoma. *Cancers (Basel).* 2023 Nov 28;15(23):5613. (IF 5,2)
82. Meixner E, Arians N, Bougatf N, Hoeltgen L, König L, Lang K, Domschke C, Wallwiener M, Lischalk JW, **Kommoss FKF**, Debus J, Hörner-Rieber J. Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors. *Tumori.* 2023 Feb;109(1):112-120. (IF 2,3)
83. **Menzel M*, Endris V*, Schwab C, Kluck K, Neumann O, Beck S, Ball M, Schaaf C, Fröhling S, Lichtner P, Schirmacher P, Kazdal D, Stenzinger A*, Budczies J*.** Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD). *Transl Oncol.* 2023 Sep;35:101706. (IF 5,0)
84. **Menzel M, Ossowski S*, Kral S*, Metzger P*, Horak P*, Marienfeld R*, Boerries M, Wolter S, Ball M, Neumann O, Armeanu-Ebinger S, Schroeder C, Matysiak U, Goldschmid H, Schipperges V, Fürstberger A, Allgäuer M, Eberhardt T, Niewöhner J, Blaumeiser A, Ploeger C, Haack TB, Tay TKY, Kelemen O, Pauli T, Kirchner M, Kluck K, Ott A, Renner M, Admard J, Gschwind A, Lassmann S, Kestler H, Fend F, Illert AL, Werner M, Möller P, Seufferlein TTW, Malek N, Schirmacher P, Fröhling S, Kazdal D*, Budczies J*, Stenzinger A*.** Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients. *NPJ Precis Oncol.* 2023 Oct 20;7(1):106. (IF 7,9)

85. Mock A*, Teleanu MV*, Kreuzfeldt S, Heilig CE, Hüllein J, Möhrmann L, Jahn A, Hanf D, Kerle IA, Singh HM, Hutter B, Uhrig S, Fröhlich M, **Neumann O**, Hartig A, Brückmann S, Hirsch S, Grund K, Dikow N, Lipka DB, **Renner M**, Bhatti IA, Apostolidis L, Schlenk RF, Schaaf CP, **Stenzinger A**, Schröck E, Hübschmann D, Heining C, Horak P, Glimm H, Fröhling S. NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. *NPJ Precis Oncol.* 2023 Oct 26;7(1):109. (IF 7,9)
86. Moesch M, Usemann J, Bruder E, Romero P, **Schwab C**, Niesler B, Tapia-Laliena MA, Khasanov R, Nisar T; Study Group NIG Retro; Holland-Cunz S, Keck S. Associations of Mucosal Nerve Fiber Innervation Density with Hirschsprung-Associated Enterocolitis: A Retrospective Three-Center Cohort Study. *Eur J Pediatr Surg.* 2023 Aug;33(4):299-309. (IF 1,8)
87. Mohamed MR, Haybaeck J, Wu H, Su H, Bartneck M, Lin C, Boekschoten MV, Boor P, **Goepfert B**, Rupp C, Strnad P, Davis RJ, Cubero FJ, Trautwein C. JNKs protect from cholestatic liver disease progression by modulating Apelin signalling. *JHEP Rep.* 2023 Jul 18;5(11):100854. (IF 8,3)
88. Morath C, Schaier M, Ibrahim E, Wang L, Kleist C, Opelz G, Süsal C, Ponath G, Aly M, Alvarez CM, Kälble F, Speer C, Benning L, Nusschag C, Pego da Silva L, Sommerer C, Hüchelhoven-Krauss A, Czock D, Mehrabi A, **Schwab C**, **Waldherr R**, Schnitzler P, Merle U, Tran TH, Scherer S, Böhmig GA, Müller-Tidow C, Reiser J, Zeier M, Schmitt M, Terness P, Schmitt A, Daniel V. Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients. *J Am Soc Nephrol.* 2023 Jan 1;34(1):160-174. (IF 13,6)
89. Motmaen I, Sereda S, **Brobeil A**, Shankar A, Braeuning A, Hasenclever D, Gattenlöhner S. Deep-learning based classification of a tumor marker for prognosis on Hodgkin's disease. *Eur J Haematol.* 2023 Nov;111(5):722-728. (IF 3,1)
90. Musa J, Willis F, Harnoss JM, Rompen IF, Sauerteig C, Kochendoerfer SM, **Grünwald TGP**, Al-Saeedi M, Schneider M, Harnoss JC. A century of retroperitoneal soft-tissue sarcoma research: From single center experience to precision oncology? A bibliometric analysis of past, present, and future perspectives. *Eur J Surg Oncol.* 2023 Sep;49(9):106948. (IF 3,8)
91. Negrao MV*, Araujo HA*, Lamberti G*, Cooper AJ*, Akhave NS*, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, **Stenzinger A**, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS*, Awad MM*, Skoulidis F*. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. *Cancer Discov.* 2023 Jul 7;13(7):1556-1571. (IF 29,1)
92. Netzer N, Eith C, Bethge O, Hielscher T, **Schwab C**, **Stenzinger A**, Gnirs R, Schlemmer HP, Maier-Hein KH, Schimmöller L, Bonekamp D. Application of a validated prostate MRI deep learning system to independent same-vendor multi-institutional data: demonstration of transferability. *Eur Radiol.* 2023 Nov;33(11):7463-7476. (IF 5,9)
93. **Neumann O**, **Lehmann U**, **Bartels S**, **Pfarr N**, **Albrecht T**, **Ilm K**, **Christmann J**, **Volckmar AL**, **Goldschmid H**, **Kirchner M**, **Allgäuer M**, **Walker M**, **Kreipe H**, **Tannapfel A**, **Weichert W**, **Schirmacher P**, **Kazdal D***, **Stenzinger A***. First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma. *J Pathol Clin Res.* 2023 Mar;9(2):100-107. (IF 4,1)
94. Niehues JM, Quirke P, West NP, Grabsch HI, van Treeck M, Schirris Y, Veldhuizen GP, Hutchins GGA, Richman SD, Foersch S, Brinker TJ, Fukuoka J, Bychkov A, Uegami W, Truhn D, Brenner H, **Brobeil A**, Hoffmeister M, Kather JN. Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study. *Cell Rep Med.* 2023 Apr 18;4(4):100980. (IF 14,3)
95. Nikitina E*, Alikhanyan K*, Neßling M*, Richter K*, Kaden S, Ernst C, Seitz S, Chuprikova L, Häfele L, Gunst K, Rahbari N, Birgin E, Rasbach E, Rahbari M, **Brobeil A**, Schenk M, Büchler M, de Villiers

- EM, Bund T, Zur Hausen H. Structural expression of bovine milk and meat factors in tissues of colorectal, lung and pancreatic cancer patients. *Int J Cancer*. 2023 Jul 1;153(1):173-182. (IF 6,4)
96. **Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Stenzinger A*, Thomas M***. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC. *J Thorac Oncol*. 2023 Jun;18(6):744-754. (IF 20,4)
 97. **Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Thomas M, Stenzinger A**. Response to "NGS, the New Global Standard?". *J Thorac Oncol*. 2023 Oct;18(10):e116-e118. (IF 20,4)
 98. Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Ely S, Fernandez-Martín C, Fineberg S, Fox SB, Gallagher WM, Giltneane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hardas A, Hart SN, Hartman J, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Siziopikou KP, Sotiriou C, **Stenzinger A**, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Adams S, Bartlett JMS, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *J Pathol*. 2023 Aug;260(5):514-532. (IF 7,3)
 99. Paluschinski M, Schira-Heinen J, **Pellegrino R**, Heij LR, Bednarsch J, Neumann UP, **Longerich T**, Stuehler K, Luedde T, Castoldi M. Uncovering Novel Roles of miR-122 in the Pathophysiology of the Liver: Potential Interaction with NRF1 and E2F4 Signaling. *Cancers (Basel)*. 2023 Aug 16;15(16):4129. (IF 5,2)
 100. Pan F, Do TD, Schmitt N, Vollherbst DF, Möhlenbruch M, Tinoush P, **Brobeil A**, Koch V, Richter GM, Pereira PL, Kauczor HU, Sommer CM. Standardizing lymphangiography and lymphatic interventions: a preclinical in vivo approach with detailed procedural steps. *CVIR Endovasc*. 2023 Mar 30;6(1):21. (IF 1,2)
 101. Park-Simon TW, Müller V, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf AD, Heil J, Huober J, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, **Sinn HP**, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Wuerstlein R, Janni W, Thill M. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023. *Breast Care (Basel)*. 2023 Aug;18(4):289-305. (IF 2,1)
 102. **Pfeffer T, Wetzel C, Kirschner P, Bartosova M, Poth T, Schwab C, Poschet G, Zemva J, Bulkescher R, Damgov I, Thiel C, Garbade SF, Klingbeil K, Peters V*, Schmitt CP***. *Carnosinase-1* Knock-Out Reduces Kidney Fibrosis in Type-1 Diabetic Mice on High Fat Diet. *Antioxidants (Basel)*. 2023 Jun 14;12(6):1270. (IF 7,0)
 103. **Pfeffer T, Wen, D, Stefanidis, K, Peters V, Ries M**. A Cross-Sectional Analysis of Registered Studies on the Promising Dipeptide Carnosine. *Int J Pept Res Ther* **29, 81 (2023)** (IF 2,5)
 104. Plum T*, Binzberger R*, Thiele R, Shang F, Postrach D, Fung C, Fortea M, Stakenborg N, Wang Z, Tappe-Theodor A, **Poth T**, MacLaren DAA, Boeckstaens G, Kuner R, Pitzer C, Monyer H, Xin C,

- Bonventre JV, Tanaka S, Voehringer D, Vanden Berghe P, Strid J, Feyerabend TB, Rodewald HR. Mast cells link immune sensing to antigen-avoidance behaviour. *Nature*. 2023 Aug;620(7974):634-642 (IF 64,8)
105. Poljo A, Kopf S, Sulaj A, **Roessler S, Albrecht T, Goepfert B**, Bojko S, Müller-Stich BP, Billeter AT. The role of bariatric surgery on beta-cell function and insulin resistance in patients with nonalcoholic fatty liver disease and steatohepatitis. *Surg Obes Relat Dis*. 2023 Dec;19(12):1421-1434. (IF 3,1)
106. Pouyiourou M*, Kraft BN*, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, **Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A**, Bochtler T, Krämer A. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. *Nat Commun*. 2023 Oct 24;14(1):6761. (IF 16,6)
107. Ramouz A, Fakour S, Jafari M, Khajeh E, Golriz M, Majlesara A, Merle U, Springfield C, **Longerich T**, Mieth M, Mehrabi A. Surgical management of primary liver cancers during the COVID-19 pandemic: overcoming the dilemma with standardization. *HPB (Oxford)*. 2023 Aug;25(8):907-914. (IF 2,9)
108. Reiter FP, Rau M, Kunzmann V, Kickuth R, Klein I, **Neumann O, Stenzinger A, Schirmacher P**, Geier A. Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations. *Z Gastroenterol*. 2023 Jan;61(1):71-75. (IF 1,3)
109. Remde H*, Schmidt-Pennington L*, Reuter M, Landwehr LS, Jensen M, Lahner H, Kimpel O, Altieri B, Laubner K, Schreiner J, Bojunga J, Kircher S, Kunze CA, Pohrt A, Teleanu MV, Hübschmann D, **Stenzinger A**, Glimm H, Fröhling S, Fassnacht M, Mai K*, Kroiss M*. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study. *Eur J Endocrinol*. 2023 Jun 7;188(6):485-493. (IF 5,8)
110. Reutter T, Fassunke J, Püsken M, Weber JP, Binot E, Eisert A, Fischer R, Nogova L, Riedel R, Schaufler D, Scharpenseel H, Scheffler M, Schulz H, Waldschmidt DT, Zander T, Merkelbach-Bruse S, **Schirmacher P**, Büttner R, Wolf J, Michels S. Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. *JCO Precis Oncol*. 2023 Apr;7:e2200467. (IF 4,6)
111. **Romanovsky E, Kluck K, Ourailidis I, Menzel M, Beck S, Ball M, Kazdal D, Christopoulos P, Schirmacher P, Stiewe T, Stenzinger A, Budczies J**. Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis. *Cell Death Discov*. 2023 Apr 14;9(1):126. (IF 7,0)
112. Rompen IF*, Nienhüser H*, Crnovrsanin N, Musa J, Haag GM, **Longerich T, Fiedler T**, Müller-Stich BP, Sisic L, Billeter AT. Clinical Characteristics and Oncological Outcomes of Surgically Treated Early-Onset Gastric Adenocarcinoma - a Retrospective Cohort Study. *J Cancer*. 2023 May 21;14(9):1470-1478. (IF 3,9)
113. Rousseau V, Einig E, Jin C, Horn J, Riebold M, **Poth T**, Jarboui MA, Flentje M, Popov N. Trim33 masks a non-transcriptional function of E2f4 in replication fork progression. *Nat Commun*. 2023 Aug 23;14(1):5143. (IF 16,6)
114. Rubio K*, Müller JM*, Mehta A, Watermann I, Olchers T, Koch I, Wessels S, Schneider MA, Araujo-Ramos T, Singh I, Kugler C, Stoleriu MG, **Kriegsmann M**, Eichhorn M, Muley T, Merkel OM, Braun T, Ammerpohl O, Reck M, Tresch A, Barreto G. Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC score. *Discov Oncol*. 2023 Oct 3;14(1):181. (IF 2,2)
115. Rüschoff J, Schildhaus HU, Rüschoff JH, Jöhrens K, Bocker-Edmonston T, Dietmaier W, Bläker H, Baretton G, Horst D, Dietel M, Hartmann A, Klauschen F, Merkelbach-Bruse S, **Stenzinger A**, Schöniger S, Tiemann M, Weichert W, Büttner R. Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität : Eine fokussierte Aktualisierung [Testing deficient mismatch repair and microsatellite instability : A focused update. German version]. *Pathologie (Heidelb)*. 2023 Sep;44(5):301-310. (IF 1,0)

116. Schäffgen B, Haller A, **Sinn HP**, Feisst M, Gomez C, Stieber A, Nees J, Togawa R, Pfob A, Hennigs A, Hederer J, Riedel F, Fastner S, Heil J, Golatta M. Conventional specimen radiography in breast-conserving therapy: a useful tool for intraoperative margin assessment after neoadjuvant therapy? *Breast Cancer Res Treat.* 2023 Aug;201(1):57-66. (IF 3,8)
117. Schaible J, Schreyer AG, Mehrabi A, **Longerich T**, Kieser M, Kreimeyer S, Klauss M, Grenacher L. Subtyping of hepatocellular adenomas using Gd-EOB-DTPA: a qualitative and quantitative analysis. *Acta Radiol.* 2023 Jul;64(7):2253-2260. (IF 1,3)
118. Schaiër M*, Morath C*, Wang L, Kleist C, Opelz G, Tran TH, Scherer S, Pham L, Ekpoom N, Süsal C, Ponath G, Kälble F, Speer C, Benning L, Nussbag C, Mahler CF, Pego da Silva L, Sommerer C, Hückelhoven-Krauss A, Czock D, Mehrabi A, **Schwab C**, **Waldherr R**, Schnitzler P, Merle U, Schwenger V, Krautter M, Kemmner S, Fischereeder M, Stangl M, Hauser IA, Kälsch AI, Krämer BK, Böhmig GA, Müller-Tidow C, Reiser J, Zeier M, Schmitt M, Terness P, Schmitt A*, Daniel V*. Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation. *Front Immunol.* 2023 Jul 11;14:1089664. (IF 7,3)
119. Schenker A, **Gutjahr E**, Lehner B, **Mechtersheimer G**, Wardelmann E, Klotz R, Kalkum E, Schiltenswolf M, Harhaus L, Renkawitz T, Panzram B. A Systematic Review and Illustrative Case Presentation of Low-Grade Myofibroblastic Sarcoma (LGMS) of the Extremities. *J Clin Med.* 2023 Nov 10;12(22):7027. (IF 3,9)
120. Schiffers C*, Zottnick S*, Förster JD, Kruse S, Yang R, **Wiethoff H**, Bozza M, Hoppe-Seyler K, Heikenwälder M, Harbottle RP, Michiels C, Riemer AB. Development of an Orthotopic HPV16-Dependent Base of Tongue Tumor Model in MHC-Humanized Mice. *Pathogens.* 2023 Jan 25;12(2):188. (IF 3,7)
121. Schneider F, Kaczorowski A, Jurcic C, **Kirchner M**, **Schwab C**, Schütz V, Görtz M, Zschäbitz S, Jäger D, **Stenzinger A**, Hohenfellner M, Duensing S, Duensing A. Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma. *Cancers (Basel).* 2023 Oct 19;15(20):5050. (IF 5,2)
122. Schnuelle P, **Schwab C**, **Waldherr R**, Zeier M, Bischofs C. Biopsy-proven acute interstitial nephritis after SARS-CoV-2 mRNA vaccination-adverse vaccine side effect or unrelated complication from self-medication? Lessons for the clinical nephrologist. *J Nephrol.* 2023 Apr;36(3):631-633. (IF 3,4)
123. Schossig P, Coskun E, **Arsenic R**, Horst D, Sehouli J, Bergmann E, Andresen N, Sigler C, Busse A, Keller U, Ochsenreither S. Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens. *Int J Mol Sci.* 2023 Jan 24;24(3):2292. (IF 5,6)
124. Schütz S, Solé-Boldo L, **Lucena-Porcel C**, Hoffmann J, **Brobeil A**, Lonsdorf AS, Rodríguez-Paredes M*, Lyko F*. Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma. *Nat Commun.* 2023 Sep 5;14(1):5413. (16,6)
125. Schütz V, Lin H, Kaczorowski A, Zschäbitz S, Jäger D, **Stenzinger A**, Duensing A, Debus J, Hohenfellner M, Duensing S. Long-Term Survival of Patients with Stage T1N0M1 Renal Cell Carcinoma. *Cancers (Basel).* 2023 Dec 6;15(24):5715. (IF 5,2)
126. **Schwab C**, **Domke LM**, **Hartmann L**, **Stenzinger A**, **Longerich T***, **Schirmacher P***. Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination. *Clin Res Cardiol.* 2023 Mar;112(3):431-440. (IF 5,0)
127. **Schwab C**, Merle U, **Schirmacher P**, **Longerich T**. Lethality of SARS-CoV-2 infection-a comparative autopsy study focusing on COVID-19 development and virus variants. *Histopathology.* 2023 Aug;83(2):242-251. (IF 6,4)
128. Schwarz S, Nientiedt C, Prigge ES, Kaczorowski A, Geisler C, **Lucena-Porcel C**, von Knebel Doeberitz M, Hohenfellner M, Duensing S. Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced Prostate Cancer. *Pathobiology.* 2023;90(5):312-321. (IF 5,0)
129. Seidensaal K, Dostal M, Kudak A, Jaekel C, Meixner E, Liermann J, Weykamp F, Hoegen P, **Mechtersheimer G**, Willis F, Schneider M, Debus J. Preoperative Dose-Escalated Intensity-

- Modulated Radiotherapy (IMRT) and Intraoperative Radiation Therapy (IORT) in Patients with Retroperitoneal Soft-Tissue Sarcoma: Final Results of a Clinical Phase I/II Trial. *Cancers (Basel)*. 2023 May 13;15(10):2747. (IF 5,2)
130. **Seker-Cin H, Tay TKY, Kazdal D, Kluck K, Ball M, Neumann O, Winter H, Herth F, Heußel CP, Savai R, Schirmacher P, Thomas M, Budczies J, Allgäuer M, Christopoulos P, Stenzinger A, Volckmar AL.** Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications. *Lung Cancer*. 2023 Oct;184:107317. (IF 5,3)
 131. **Sinn HP, Varga Z.** Triple-negatives Mammakarzinom : Klassifikation, aktuelle Konzepte und therapierelevante Faktoren [Triple-negative breast cancer : Classification, current concepts, and therapy-related factors]. *Pathologie (Heidelb)*. 2023 Feb;44(1):32-38. (IF 1,0)
 132. Steen S*, Semmelmayr K*, **Flechtenmacher C**, Hoffmann J, Freier K, Horn D, Hess J, Freudlsperger C, Moratin J. Dynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma. *Int J Mol Sci*. 2023 Nov 16;24(22):16386. (IF 5,6)
 133. Steiert TA, Parra G, Gut M, Arnold N, Trotta JR, Tonda R, Moussy A, Gerber Z, Abuja PM, Zatloukal K, Röcken C, Folseraas T, Grimsrud MM, Vogel A, **Goepfert B, Roessler S**, Hinz S, Schafmayer C, Rosenstiel P, Deleuze JF, Gut IG, Franke A, Forster M. A critical spotlight on the paradigms of FFPE-DNA sequencing. *Nucleic Acids Res*. 2023 Aug 11;51(14):7143-7162. (IF 14,9)
 134. Stellmach C, Sass J, Auber B, Boeker M, Wienker T, Heide AJ, Benary M, Schumacher S, Ossowski S, Klauschen F, Möller Y, Schmutzler R, Ustjanzew A, Werner P, **Tomczak A**, Hölter T, Thun S. Creation of a structured molecular genomics report for Germany as a local adaption of HL7's Genomic Reporting Implementation Guide. *J Am Med Inform Assoc*. 2023 May 19;30(6):1179-1189. (IF 6,4)
 135. Stemberge N, Doolan BJ, Lavalley ME, **Hausser I**, Pope FM, Seneviratne SL, Winship IM, Burrows NP. The role of cutaneous manifestations in the diagnosis of the Ehlers-Danlos syndromes. *Skin Health Dis*. 2022 Jul 15;3(1):e140. eCollection 2023 Feb. (print in 2023) (no IF)
 136. **Stenzinger A, Cuffel B, Paracha N, Vail E, Garcia-Foncillas J, Goodman C, Lassen U, Vassal G, Sullivan SD.** Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator. *Oncologist*. 2023 May 8;28(5):e242-e253. (IF 5,8)
 137. **Stenzinger A, Moltzen EK, Winkler E, Molnar-Gabor F, Malek N, Costescu A, Jensen BN, Nowak F, Pinto C, Ottersen OP, Schirmacher P, Nordborg J, Seufferlein T, Fröhling S, Edsjö A, Garcia-Foncillas J, Normanno N, Lundgren B, Friedman M, Bolanos N, Tatton-Brown K, Hill S, Rosenquist R.** Implementation of precision medicine in healthcare-A European perspective. *J Intern Med*. 2023 Oct;294(4):437-454. (IF 11,1)
 138. **Stögbauer F, Beck S*, Ourailidis I, Hess J, Poremba C, Lauterbach M, Wollenberg B, Buchberger AMS, Jesinghaus M, Schirmacher P, Stenzinger A, Weichert W, Boxberg M, Budczies J.** Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer. *Br J Cancer*. 2023 Jun;128(12):2295-2306. (IF 8,8)
 139. **Stögbauer F, Geß B, Brambs C, Lautizi M, Kacprowski T, Ourailidis I, Bronger H, Kiechle M, Noske A, Keller G, Jesinghaus M, Poremba C, Weichert W, Boxberg M.** Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients. *Cancers (Basel)*. 2023 Jul 28;15(15):3832. (IF 5,2)
 140. Sturm D, Capper D, Andreiuolo F, Gessi M, **Kölsche C**, Reinhardt A, Sievers P, Wefers AK, Ebrahimi A, Suwala AK, Gielen GH, Sill M, Schrimpf D, Stichel D, Hovestadt V, Daenekas B, Rode A, Hamelmann S, Previti C, Jäger N, Buchhalter I, Blattner-Johnson M, Jones BC, Warmuth-Metz M, Bison B, Grund K, Sutter C, Hirsch S, Dikow N, Hasselblatt M, Schüller U, Koch A, Gerber NU, White CL, Buntine MK, Kinross K, Algar EM, Hansford JR, Gottardo NG, Schuhmann MU, Thomale UW, Hernáiz Driever P, Gnekow A, Witt O, Müller HL, Calaminus G, Fleischhack G, Kordes U, Mynarek M, Rutkowski S, Frühwald MC, Kramm CM, von Deimling A, Pietsch T, Sahn F, Pfister SM, Jones DTW. Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. *Nat Med*. 2023 Apr;29(4):917-926. (IF 82,9)

141. Tabler CT, Lodd E, Bennewitz K, Middel CS, Erben V, Ott H, **Poth T**, Fleming T, Morgenstern J, **Hausser I**, Sticht C, Poschet G, Szendroedi J, Nawroth PP, Kroll J. Loss of glyoxalase 2 alters the glucose metabolism in zebrafish. *Redox Biol.* 2023 Feb;59:102576. (IF 11,4)
142. **Tang Y, Thiess L, Weiler SME, Tóth M, Rose F, Merker S, Ruppert T, Schirmacher P, Breuhahn K.** α -catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration. *Cell Commun Signal.* 2023 Jun 28;21(1):162. (IF 8,4)
143. Tavakoli AA, Hielscher T, Badura P, Görtz M, Kuder TA, Gnirs R, **Schwab C**, Hohenfellner M, Schlemmer HP, Bonekamp D. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer. *Radiology.* 2023 Jan;306(1):186-199. (IF 19,7)
144. Tawk B, Rein K, Schwager C, Knoll M, Wirkner U, Hörner-Rieber J, Liermann J, Kurth I, Balermipas P, Rödel C, Linge A, Löck S, Lohaus F, Tinhofer I, Krause M, Stuschke M, Grosu AL, Zips D, Combs SE, Belka C, **Stenzinger A**, Herold-Mende C, Baumann M, **Schirmacher P**, Debus J, Abdollahi A. DNA-Methylome-Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy. *Clin Cancer Res.* 2023 Aug 15;29(16):3051-3064. (IF 11,5)
145. Teleanu MV, Fuss CT, Paramasivam N, Pirmann S, Mock A, Terkamp C, Kircher S, Landwehr LS, Lenschow C, Schlegel N, **Stenzinger A**, Jahn A, Fassnacht M, Glimm H, Hübschmann D, Fröhling S, Kroiss M. Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling. *Mol Oncol.* 2023 Jul;17(7):1343-1355. (IF 6,6)
146. Thagaard J*, Broeckx G*, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khuroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, Azmoudeh-Ardalan F, Badve S, Baharun NB, Balslev E, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Chon U Cheang M, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dahl AB, Dantas Portela FL, Deman F, Demaria S, Doré Hansen J, Dudgeon SN, Ebstrup T, Elghazawy M, Fernandez-Martín C, Fox SB, Gallagher WM, Giltane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hauberg S, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papatomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Puztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Roslind A, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Scott E, Siziopikou KP, Sotiriou C, **Stenzinger A**, Sughayer MA, Sur D, Fineberg S, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Zin RM, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *J Pathol.* 2023 Aug;260(5):498-513. (IF 7,3)
147. Theobald V, Grünig E, Benjamin N, Seyfarth HJ, Halank M, Schneider MA, Richtmann S, **Kazdal D**, Hinderhofer K, Xanthouli P, Egenlauf B, Harutyunova S, Hoepfer MM, Jonigk D, Sparla R, Muckenthaler MU, Eichstaedt CA. Is iron deficiency caused by *BMP2* mutations or dysfunction in pulmonary arterial hypertension patients? *Pulm Circ.* 2023 Jun 7;13(2):e12242. (IF 2,6)
148. Thill M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf AD, Heil J, Huober J, Jackisch C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, **Sinn HP**, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Würstlein R, Janni W, Park-Simon TW. AGO Recommendations for the Diagnosis and Treatment

- of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. *Breast Care* (Basel). 2023 Aug;18(4):306-315. (IF 2,1)
149. Tjaden C, Hinz U, Klaiber U, Heger U, Springfield C, **Goepfert B**, Schmidt T, Mehrabi A, Strobel O, Berchtold C, Schneider M, Diener M, Neoptolemos JP, Hackert T, Büchler MW. Distal Bile Duct Cancer: Radical (R0 > 1 mm) Resection Achieves Favorable Survival. *Ann Surg*. 2023 Jan 1;277(1):e112-e118. (IF 10,1)
150. **Tóth M**, **Benedek AE**, **Longerich T**, **Seitz HK**. *Ashwagandha*-induced acute liver injury: A case report. *Clin Case Rep*. 2023 Mar 14;11(3):e7078. (IF 0,7)
151. Varga Z, **Sinn P**, Lebeau A. B3-Läsionen der Mamma: Histologische, klinische und epidemiologische Aspekte : Update [B3 lesions of the breast: histological, clinical, and epidemiological aspects : Update]. *Pathologie* (Heidelb). 2023 Feb;44(1):5-16. (IF 1,0)
152. Veinalde R*, Pidelaserra-Martí G*, Moulin C, Tan CL, Schäfer TE, Kang N, Ball CR, **Leichsenring J**, **Stenzinger A**, Kaderali L, Jäger D, Ungerechts G, Engeland CE. Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. *Front Immunol*. 2023 Jan 16;13:1096162. (IF 7,3)
153. Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, Primrose JN, Rimassa L, **Stenzinger A**, Valle JW, Ducreux M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2023 Feb;34(2):127-140. (IF 50,5)
154. Vogel A, Segatto O, **Stenzinger A**, Saborowski A. FGFR2 Inhibition in Cholangiocarcinoma. *Annu Rev Med*. 2023 Jan 27;74:293-306. (IF 10,5)
155. Vucur M, Ghallab A, Schneider AT, Adili A, Cheng M, Castoldi M, Singer MT, Büttner V, Keysberg LS, Küsgens L, Kohlhepp M, Görg B, Gallage S, Barragan Avila JE, Unger K, Kordes C, Leblond AL, Albrecht W, Loosen SH, Lohr C, Jördens MS, Babler A, Hayat S, Schumacher D, Koenen MT, Govaere O, Boekschoten MV, Jörs S, Villacorta-Martin C, Mazzaferro V, Llovet JM, Weiskirchen R, Kather JN, Starlinger P, Trauner M, Luedde M, Heij LR, Neumann UP, Keitel V, Bode JG, Schneider RK, Tacke F, Levkau B, Lammers T, Fluegen G, Alexandrov T, Collins AL, Nelson G, Oakley F, Mann DA, Roderburg C, **Longerich T**, Weber A, Villanueva A, Samson AL, Murphy JM, Kramann R, Geisler F, Costa IG, Hengstler JG, Heikenwalder M, Luedde T. Sublethal necroptosis signaling promotes inflammation and liver cancer. *Immunity*. 2023 Jul 11;56(7):1578-1595.e8. (IF 32,4)
156. Wang Y, Chen SY, Ta M, Senz J, Tao LV, Thornton S, Tamvada N, Yang W, Moscovitz Y, Li E, Guo J, Shen C, Douglas JM, Ei-Naggar AM, **Kommoss FKF**, Underhill TM, Singh N, Gilks CB, Morin GB, Huntsman DG. Biallelic Dicer1 Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of DICER1 Syndrome-Associated Cancer. *Cancer Res*. 2023 Nov 1;83(21):3517-3528. (IF 11,2)
157. Weir A*, Kang EY*, Meagher NS, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Gentry-Maharaj A, Ryan A, Singh N, Widschwendter M, Alsop J, Anglesio MS, Beckmann MW, Berger J, Bisinotto C, Boros J, Brand AH, Brenton JD, Brooks-Wilson A, Carney ME, Cunningham JM, Cushing-Haugen KL, Cybulski C, Elishaev E, Erber R, Fereday S, Fischer A, Paz-Ares L, Gayarre J, Gilks BC, Grube M, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J, Hernandez BY, Heublein S, Huang Y, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, **Kommoss FKF**, Koziak JM, Kraemer B, Le ND, Lesnock J, Lester J, Lubiński J, Menkiszak J, Ney B, Olawaiye A, Orsulic S, Osorio A, Robles-Díaz L, Ruebner M, Shah M, Sharma R, Shvetsov YB, Steed H, Talhouk A, Taylor SE, Traficante N, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Benitez J, Berchuck A, Bowtell DD, Candido Dos Reis FJ, Cook LS, DeFazio A; AOCs group; Doherty JA, Fasching PA, García MJ, Goode EL, Goodman MT, Gronwald J, Huntsman DG, Karlan BY, Kommoss S, Modugno F, Schildkraut JM, **Sinn HP**, Staebler A, Kelemen LE, Ford CE, Menon U, Pharoah PDP, Köbel M*, Ramus SJ*. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study. *Br J Cancer*. 2023 Jan;128(1):137-147. (IF 8,8)
158. Weisshaar N, Ma S, Ming Y, Madi A, Mieg A, Hering M, Zettl F, Mohr K, Ten Bosch N, Stichling D, Buettner M, Poschet G, Klinker G, Schulz M, Kunze-Rohrbach N, Kerber C, **Klein IM**, Wu J, Wang

- X, Cui G. The malate shuttle detoxifies ammonia in exhausted T cells by producing 2-ketoglutarate. *Nat Immunol.* 2023 Nov;24(11):1921-1932. (IF 30,5)
159. Westhoff CC, Ramaswamy A, Kalder M, Lebeau A, **Sinn P**, Denkert C. Immunhistologie in der Mammadiagnostik : Strategien für effiziente Diagnostik [Immunohistology in breast diagnostics : Strategies for efficient diagnostics]. *Pathologie (Heidelb).* 2023 Feb;44(1):17-31. German. (IF 1,0)
160. Westphal D, Meinhardt M, Grützmann K, Schöne L, Steininger J, Neuhaus LT, Wiegel M, Schrimpf D, Aust DE, Schröck E, Baretton GB, Beissert S, Juratli TA, Schackert GG, Gravemeyer J, Becker JC, von Deimling A, **Koelsche C**, Klink B, Meier F, Schulz A, Muders MH, Seifert M. Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma Metastases. *J Invest Dermatol.* 2023 Jul;143(7):1233-1245.e17. (IF 6,5)
161. **Wiethoff H**, **Mohr I**, **Fichtner A**, **Merle U**, **Schirmacher P**, **Weiss KH**, **Longerich T**. Metallothionein: a game changer in histopathological diagnosis of Wilson disease. *Histopathology.* 2023 Dec;83(6):936-948. (IF 6,4)
162. Willis F, Buck L, Musa J, Hinz U, **Mechtersheimer G**, Seidensaal K, Fröhling S, Büchler MW, Schneider M. Long-term quality of life after resection of retroperitoneal soft tissue sarcoma. *Eur J Surg Oncol.* 2023 Nov;49(11):106977. (IF 3,8)
163. Witzel HR, Schwittai IMG, Hartmann N, Mueller S, Schattenberg JM, Gong XM, Backs J, **Schirmacher P**, Schuppan D, Roth W, Straub BK. PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent with ATGL. *Cells.* 2023, 12, 73. (IF 6,0)
164. Wong NKY, Llaurodo Fernandez M, **Kommos FKF**, Praveen Kumar P, Kim H, Liu J, Zhang G, Coatham M, Lin YY, Haegert AM, Volik S, Le Bihan S, Collins CC, Fu Y, Postovit LM, von Deimling A, Wu R, Xue H, Wang Y, Köbel M, Carey MS, Lee CH. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma. *Gynecol Oncol.* 2023 Sep;176:162-172. (IF 4,7)
165. Xu Z, Huang Z, Zhang Y, Sun H, Hinz U, Heger U, Loos M, Gonzalez FJ, Hackert T, **Bergmann F***, Fortunato F*. Farnesoid X receptor activation inhibits pancreatic carcinogenesis. *Biochim Biophys Acta Mol Basis Dis.* 2023 Oct;1869(7):166811. (IF 6,2)
166. Ye L, Schneider JS, Ben Khaled N, **Schirmacher P**, Seifert C, Frey L, He Y, Geier A, De Toni EN, Zhang C, Reiter FP. Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management. *Liver Cancer.* 2023 Apr 24;13(1):6-28. (IF 13,8)
167. Yılmaz Topçuoğlu MS, Hornberger C, **Lucena-Porcel C**, Baumann I. Das komplizierte kindliche Mittelohrhämangiom [The complex pediatric middle ear hemangioma]. *HNO.* 2023 Apr;71(4):270-273. (IF 0,9)
168. Zhang C, Bartosova M, Marinovic I, **Schwab C**, Schaefer B, Vondrak K, Ariceta G, Zaloszc A, Ranchin B, Taylan C, Büscher R, Oh J, Mehrabi A, Schmitt CP. Peritoneal transformation shortly after kidney transplantation in pediatric patients with preceding chronic peritoneal dialysis. *Nephrol Dial Transplant.* 2023 Sep 29;38(10):2170-2181. (IF 6,1)
169. Zhang KS*, Mayer P*, Glemser PA, Tavakoli AA, Keymling M, Rotkopf LT, Meinzer C, Görtz M, Kauczor HU, Hielscher T, **Stenzinger A**, Bonekamp D, Hohenfellner M, Schlemmer HP. Are T2WI PI-RADS sub-scores of transition zone prostate lesions biased by DWI information? A multi-reader, single-center study. *Eur J Radiol.* 2023 Oct;167:111026. (IF 1,8)
170. Zhang KS, Neelsen CJO, Wennmann M, Glemser PA, Hielscher T, Weru V, Görtz M, Schütz V, **Stenzinger A**, Hohenfellner M, Schlemmer HP, Bonekamp D. Same-day repeatability and Between-Sequence reproducibility of Mean ADC in PI-RADS lesions. *Eur J Radiol.* 2023 Aug;165:110898. (IF 1,8)
171. Zhang Q*, Xiong L*, Wei T, Liu Q, Yan L, Chen J, Dai L, Shi L, Zhang W, Yang J, **Roessler S**, Liu L. Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma. *Oncogene.* 2023 May;42(19):1509-1523. (IF 8,0)
172. Zheng X*, Sarode P*, Weigert A, Turkowski K, Chelladurai P, Günther S, Kuenne C, Winter H, **Stenzinger A**, Reu S, Grimminger F, Stiewe T, Seeger W, Pullamsetti SS, Savai R. The HDAC2-SP1

- Axis Orchestrates Protumor Macrophage Polarization. *Cancer Res.* 2023 Jul 14;83(14):2345-2357. (IF 11,2)
173. Zhou X*, An J*, Kurilov R*, Brors B, Hu K, Peccerella T, **Roessler S**, Pfütze K, Schulz A, Wolf S, Hohmann N, Theile D, Sauter M, Burhenne J, Ei S, Heger U, Strobel O, Barry ST, Springfield C, Tjaden C, **Bergmann F**, Büchler M, Hackert T, Fortunato F, Neoptolemos JP, Bailey P. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. *Nat Cancer.* 2023 Sep;4(9):1362-1381. (IF 22,7)

Book chapters

Longerich T, Schirmacher P. Molecular Pathology of Livers Tumors. In : *Molecular Surgical Pathology 2023*; Vol: 8, S. 201 – 230, ISBN : 978-3-031-351118-1 ,
doi: 10.1007/978-3-031-351118-1